The historic rise of Viagra has consistently remained a example of pharmaceutical success, but its legacy within the broader sector now presents questions about long-term returns . Generic versions are eroding patent protection , leading to concerns that investing in companies heavily reliant to Viagra's former standing could be a dangerous move ,